Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience

Chin Med J (Engl). 2017 Jan 20;130(2):239-241. doi: 10.4103/0366-6999.198017.

Authors

Tian-Jiao Guo¹, Xiao-Jun Huang², Lei Wen², Jin Lu²

Affiliations

¹ Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044; Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 100038, China.
² Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.

No abstract available

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Bortezomib / therapeutic use*
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*

Substances

Antineoplastic Agents
Bortezomib